Ref (type)	Population	Outcome, Interventions	Results and statistical analysis	Effect size	Favours
Symptom severity
Systematic review	586 people 3 RCTs in this analysis	No clinically important change (as defined by original studies) with amisulpride (100–1000 mg/day) with risperidone (1–10 mg/day) Absolute results not reported	RR 0.89 95% CI 0.67 to 1.20		Not significant
Systematic review	310 people Data from 1 RCT	<50% reduction in Positive and Negative Syndrome Scale (PANSS) total score with amisulpride (100–1000 mg/day) with risperidone (1–10 mg/day) Absolute results not reported	RR 0.81 95% CI 0.65 to 1.00		Not significant
Systematic review	48 people Data from 1 RCT	20% reduction in PANSS total score short term with amisulpride (100–1000 mg/day) with risperidone (1–10 mg/day) Absolute results not reported	RR 1.45 95% CI 0.59 to 3.54		Not significant
Systematic review	310 people Data from 1 RCT	<50% reduction in Brief Psychiatric Rating Scale (BPRS) score with amisulpride (100–1000 mg/day) with risperidone (1–10 mg/day) Absolute results not reported	RR 0.78 95% CI 0.62 to 0.98 NNT 8 95% CI 4 to 100	Small effect size	amisulpride
Systematic review	228 people Data from 1 RCT	<40% reduction in BPRS score short term with amisulpride (100–1000 mg/day) with risperidone (1–10 mg/day) Absolute results not reported	RR 0.78 95% CI 0.56 to 1.09		Not significant
Systematic review	519 people 3 RCTs in this analysis	Mean difference in PANSS positive symptom subscore with amisulpride (100–1000 mg/day) with risperidone (1–10 mg/day) Absolute results not reported	Mean difference –0.03 95% CI –1.29 to +1.24		Not significant
Systematic review	519 people 3 RCTs in this analysis	Mean difference in PANSS negative symptom subscore with amisulpride (100–1000 mg/day) with risperidone (1–10 mg/day) Absolute results not reported	Mean difference –1.0 95% CI –2.11 to +0.11		Not significant
RCT	38 older people	Reduction in PANSS score 6 weeks 28% with amisulpride (100–400 mg/day) 29% with risperidone (1–4 mg/day) Absolute numbers not reported	P value not reported
RCT	38 older people	Proportion of people who responded to treatment 10/25 (40%) with amisulpride (100–400 mg/day) 5/13 (38%) with risperidone (1–4 mg/day)	P value not reported
RCT	38 older people	BPRS score 6 weeks with amisulpride (100–400 mg/day) with risperidone (1–4 mg/day) Absolute results not reported	Reported as not significant P value not reported		Not significant
RCT	38 older people	Mini-Mental State Examination 6 weeks with amisulpride (100–400 mg/day) with risperidone (1–4 mg/day) Absolute results not reported	Reported as not significant P value not reported		Not significant